Chylomicrons: Advances in biology, pathology, laboratory testing, and therapeutics

Clinica Chimica Acta

Volumn 455, Issue , 2016, Pages 134-148

  Julve, Josep ^a,b,c   Martín Campos, Jesús M ^a,b,c   Escolà Gil, Joan Carles ^a,b,c   Blanco Vaca, Francisco ^a,b,c,d  

^a BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Abetalipoproteinemia; Atherosclerosis; Chylomicron; Chylomicron retention disease; Enterocyte; Hypobetalipoproteinemia; Laboratory testing; Therapy; Triglyceride; Type I hyperlipidemia; Type V hyperlipidemia

Indexed keywords

ALIPOGENE TIPARVOVEC; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN A5; APOLIPOPROTEIN B48; APOLIPOPROTEIN C; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHAPERONE; CHYLOMICRON; COAT PROTEIN COMPLEX II; FATTY ACID; FATTY ACID BINDING PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN 1; LIPASE MATURATION FACTOR 1 PROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; OMEGA 3 FATTY ACID; SORTILIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABETALIPOPROTEINEMIA; AUTOIMMUNE DISEASE; AUTOIMMUNE HYPERCHYLOMICRONEMIA; AUTOSOMAL RECESSIVE DISORDER; BIOCHEMICAL ANALYSIS; CATABOLISM; CHYLOMICRON RETENTION DISEASE; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; FAMILIAL COMBINED HYPOLIPIDEMIA; FAMILIAL HYPOBETALIPOPROTEINEMIA; GENE THERAPY; GENETIC SCREENING; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; HYPERLIPOPROTEINEMIA TYPE 3; HYPOLIPEMIA; INTRACARDIAC THROMBOSIS; LABORATORY TEST; LIPID ABSORPTION; LIPID COMPOSITION; LIPOGENESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN SECRETION; PROTEIN TRANSPORT; REVIEW; STRUCTURE ACTIVITY RELATION; CHEMISTRY; HYPERLIPIDEMIAS; METABOLISM;

APOLIPOPROTEINS; CHYLOMICRONS; GENETIC THERAPY; HUMANS; HYPERLIPIDEMIAS;

EID: 84958279785     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2016.02.004     Document Type: Review

References (168)

1. Nakajima K., Nagamine T., Fujita M.Q., Ai M., Tanaka A., Schaefer E. Apolipoprotein B-48: a unique marker of chylomicron metabolism. Adv. Clin. Chem. 2014, 64:117-177.
2. Iqbal J., Hussain M.M. Intestinal lipid absorption. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E1183-E1194.
3. Lossow W.J., Lindgren F.T., Murchio J.C., Stevens G.R., Jensen L.C. Particle size and protein content of six fractions of the Sf 20 plasma lipoproteins isolated by density gradient centrifugation. J. Lipid Res. 1969, 10:68-76.
4. Hayashi H., Fujimoto K., Cardelli J.A., Nutting D.F., Bergstedt S., Tso P. Fat feeding increases size, but not number, of chylomicrons produced by small intestine. Am. J. Physiol. 1990, 259:G709-G719.
5. Wood P., Imaichi K., Knowles J., Michaels G., Kinsell L. The lipid composition of human plasma chylomicrons. J. Lipid Res. 1964, 5:225-231.
6. Sakr S.W., Attia N., Haourigui M., et al. Fatty acid composition of an oral load affects chylomicron size in human subjects. Br. J. Nutr. 1997, 77:19-31.
7. Lairon D., Lopez-Miranda J., Williams C. Methodology for studying postprandial lipid metabolism. Eur. J. Clin. Nutr. 2007, 61:1145-1161.
8. Dash S., Xiao C., Morgantini C., Lewis G.F. New insights into the regulation of chylomicron production. Annu. Rev. Nutr. 2015, 35:265-294.
9. Griffo E., Di Marino L., Patti L., et al. Test meals rich in marine long-chain n-3 polyunsaturated fatty acids increase postprandial chylomicron response. Nutr. Res. 2014, 34:661-666.
10. Miyoshi T., Noda Y., Ohno Y., et al. Omega-3 fatty acids improve postprandial lipemia and associated endothelial dysfunction in healthy individuals-a randomized cross-over trial. Biomed. Pharmacother. 2014, 68:1071-1077.
11. Boren J., Matikainen N., Adiels M., Taskinen M.R. Postprandial hypertriglyceridemia as a coronary risk factor. Clin. Chim. Acta 2014, 431:131-142.
12. Hussain M.M., Kedees M.H., Singh K., Athar H., Jamali N.Z. Signposts in the assembly of chylomicrons. Front. Biosci. 2001, 6:D320-D331.
13. Karupaiah T., Sundram K. Modulation of human postprandial lipemia by changing ratios of polyunsaturated to saturated (P/S) fatty acid content of blended dietary fats: a cross-over design with repeated measures. Nutr. J. 2013, 12:122.
14. Bonham M.P., Linderborg K.M., Dordevic A., et al. Lipidomic profiling of chylomicron triacylglycerols in response to high fat meals. Lipids 2013, 48:39-50.
15. Mahley R.W., Innerarity T.L., Rall S.C., Weisgraber K.H. Plasma lipoproteins: apolipoprotein structure and function. J. Lipid Res. 1984, 25:1277-1294.
16. Marcel Y.L., Innerarity T.L., Spilman C., Mahley R.W., Protter A.A., Milne R.W. Mapping of human apolipoprotein B antigenic determinants. Arteriosclerosis 1987, 7:166-175.
17. Schonfeld G., Bell E., Alpers D.H. Intestinal apoproteins during fat absorption. J. Clin. Invest. 1978, 61:1539-1550.
18. Abumrad N.A., Davidson N.O. Role of the gut in lipid homeostasis. Physiol. Rev. 2012, 92:1061-1085.
19. Jaschke A., Chung B., Hesse D., et al. The GTPase ARFRP1 controls the lipidation of chylomicrons in the Golgi of the intestinal epithelium. Hum. Mol. Genet. 2012, 21:3128-3142.
20. Blanco-Vaca F., Escola-Gil J.C., Martin-Campos J.M., Julve J. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J. Lipid Res. 2001, 42:1727-1739.
21. Martin-Campos J.M., Escola-Gil J.C., Ribas V., Blanco-Vaca F. Apolipoprotein A-II, genetic variation on chromosome 1q21-q24, and disease susceptibility. Curr. Opin. Lipidol. 2004, 15:247-253.
22. Weng W., Breslow J.L. Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:14788-14794.
23. Boisfer E., Lambert G., Atger V., et al. Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis. J. Biol. Chem. 1999, 274:11564-11572.
24. Dugue-Pujol S., Rousset X., Pastier D., et al. Human apolipoprotein A-II associates with triglyceride-rich lipoproteins in plasma and impairs their catabolism. J. Lipid Res. 2006, 47:2631-2639.
25. Julve J., Escola-Gil J.C., Rotllan N., et al. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome. Arterioscler. Thromb. Vasc. Biol. 2010, 30:232-238.
26. Castellani L.W., Nguyen C.N., Charugundla S., et al. Apolipoprotein AII is a regulator of very low density lipoprotein metabolism and insulin resistance. J. Biol. Chem. 2008, 283:11633-11644.
27. Deng X., Walker R.G., Morris J., Davidson W.S., Thompson T.B. Role of conserved proline residues in human apolipoprotein A-IV structure and function. J. Biol. Chem. 2015, 290:10689-10702.
28. Pan X., Hussain M.M. Gut triglyceride production. Biochim. Biophys. Acta 1821, 2012:727-735.
29. Karathanasis S.K., Yunis I., Zannis V.I. Structure, evolution, and tissue-specific synthesis of human apolipoprotein AIV. Biochemistry 1986, 25:3962-3970.
30. Green P.H., Glickman R.M., Riley J.W., Quinet E. Human apolipoprotein A-IV. Intestinal origin and distribution in plasma. J. Clin. Invest. 1980, 65:911-919.
31. Kohan A.B., Wang F., Lo C.M., Liu M., Tso P. ApoA-IV: current and emerging roles in intestinal lipid metabolism, glucose homeostasis, and satiety. Am. J. Physiol. Gastrointest. Liver Physiol. 2015, 308:G472-G481.
32. Wang F., Kohan A.B., Lo C.M., Liu M., Howles P., Tso P. Apolipoprotein A-IV: a protein intimately involved in metabolism. J. Lipid Res. 2015, 56:1403-1418.
33. Goldberg I.J., Scheraldi C.A., Yacoub L.K., Saxena U., Bisgaier C.L. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. J. Biol. Chem. 1990, 265:4266-4272.
34. Nilsson S.K., Heeren J., Olivecrona G., Merkel M. Apolipoprotein A-V; a potent triglyceride reducer. Atherosclerosis 2011, 219:15-21.
35. Pruneta-Deloche V., Ponsin G., Groisne L., Fruchart-Najib J., Lagarde M., Moulin P. Postprandial increase of plasma apoAV concentrations in Type 2 diabetic patients. Atherosclerosis 2005, 181:403-405.
36. Almeda-Valdes P., Cuevas-Ramos D., Mehta R., et al. Factors associated with postprandial lipemia and apolipoprotein A-V levels in individuals with familial combined hyperlipidemia. BMC Endocr. Disord. 2014, 14:90.
37. Fu J., Gaetani S., Oveisi F., et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 2003, 425:90-93.
38. Vu-Dac N., Gervois P., Jakel H., et al. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J. Biol. Chem. 2003, 278:17982-17985.
39. Fu J., Astarita G., Gaetani S., et al. Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J. Biol. Chem. 2007, 282:1518-1528.
40. Zhang L.S., Xu M., Yang Q., Ryan R.O., Howles P., Tso P. Apolipoprotein A-V deficiency enhances chylomicron production in lymph fistula mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2015, 308:G634-G642.
41. Zhang L.S., Sato H., Yang Q., et al. Apolipoprotein A-V is present in bile and its secretion increases with lipid absortion in Sprague-Dawley rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2015, 309:G918-G925.
42. Jong M.C., Hofker M.H., Havekes L.M. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler. Thromb. Vasc. Biol. 1999, 19:472-484.
43. Schaefer E.J., Eisenberg S., Levy R.I. Lipoprotein apoprotein metabolism. J. Lipid Res. 1978, 19:667-687.
44. Windler E., Havel R.J. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J. Lipid Res. 1985, 26:556-565.
45. Larsson M., Vorrsjo E., Talmud P., Lookene A., Olivecrona G. Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. J. Biol. Chem. 2013, 288:33997-34008.
46. Kei A.A., Filippatos T.D., Tsimihodimos V., Elisaf M.S. A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism 2012, 61:906-921.
47. LaRosa J.C., Levy R.I., Herbert P., Lux S.E., Fredrickson D.S. A specific apoprotein activator for lipoprotein lipase. Biochem. Biophys. Res. Commun. 1970, 41:57-62.
48. Norata G.D., Tsimikas S., Pirillo A., Catapano A.L. Apolipoprotein C-III: from pathophysiology to pharmacology. Trends Pharmacol. Sci. 2015, 36:675-687.
49. Heeren J., Beisiegel U., Grewal T. Apolipoprotein E recycling: implications for dyslipidemia and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2006, 26:442-448.
50. Williams K.J., Chen K. Recent insights into factors affecting remnant lipoprotein uptake. Curr. Opin. Lipidol. 2010, 21:218-228.
51. Gonzales J.C., Gordts P.L., Foley E.M., Esko J.D. Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans. J. Clin. Invest. 2013, 123:2742-2751.
52. Flood C., Gustafsson M., Richardson P.E., Harvey S.C., Segrest J.P., Boren J. Identification of the proteoglycan binding site in apolipoprotein B48. J. Biol. Chem. 2002, 277:32228-32233.
53. Weisgraber K.H., Rall S.C. Human apolipoprotein B-100 heparin-binding sites. J Biol Chem 1987, 262:11097-11103.
54. Hill J.S., Yang D., Nikazy J., Curtiss L.K., Sparrow J.T., Wong H. Subdomain chimeras of hepatic lipase and lipoprotein lipase. localization of heparin and cofactor binding. J. Biol. Chem. 1998, 273:30979-30984.
55. Masuda D., Hirano K., Oku H., et al. Chylomicron remnants are increased in the postprandial state in CD36 deficiency. J. Lipid Res. 2009, 50:999-1011.
56. Yen C.L., Cheong M.L., Grueter C., et al. Deficiency of the intestinal enzyme acyl CoA: monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding. Nat. Med. 2009, 15:442-446.
57. Haas J.T., Winter H.S., Lim E., et al. DGAT1 mutation is linked to a congenital diarrheal disorder. J. Clin. Invest. 2012, 122:4680-4684.
58. Iqbal J., Rudel L.L., Hussain M.M. Microsomal triglyceride transfer protein enhances cellular cholesteryl esterification by relieving product inhibition. J. Biol. Chem. 2008, 283:19967-19980.
59. Mitchell D.M., Zhou M., Pariyarath R., et al. Apoprotein B100 has a prolonged interaction with the translocon during which its lipidation and translocation change from dependence on the microsomal triglyceride transfer protein to independence. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:14733-14738.
60. Antonny B., Schekman R. ER export: public transportation by the COPII coach. Curr. Opin. Cell Biol. 2001, 13:438-443.
61. Strong A., Patel K., Rader D.J. Sortilin and lipoprotein metabolism: making sense out of complexity. Curr. Opin. Lipidol. 2014, 25:350-357.
62. Nilsson S.K., Christensen S., Raarup M.K., Ryan R.O., Nielsen M.S., Olivecrona G. Endocytosis of apolipoprotein A-V by members of the low density lipoprotein receptor and the VPS10p domain receptor families. J. Biol. Chem. 2008, 283:25920-25927.
63. Carlo A.S., Gustafsen C., Mastrobuoni G., et al. The pro-neurotrophin receptor sortilin is a major neuronal apolipoprotein E receptor for catabolism of amyloid-beta peptide in the brain. J. Neurosci. 2013, 33:358-370.
64. Kjolby M., Andersen O.M., Breiderhoff T., et al. Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export. Cell Metab. 2010, 12:213-223.
65. Brahm A.J., Hegele R.A. Chylomicronaemia-current diagnosis and future therapies. Nat. Rev. Endocrinol. 2015, 11:352-362.
66. Willnow T.E. Mechanisms of hepatic chylomicron remnant clearance. Diabet. Med. 1997, 14(Suppl. 3):S75-S80.
67. Diard P., Malewiak M.I., Lagrange D., Griglio S. Hepatic lipase may act as a ligand in the uptake of artificial chylomicron remnant-like particles by isolated rat hepatocytes. Biochem. J. 1994, 299(Pt 3):889-894.
68. Dallinga-Thie G.M., Franssen R., Mooij H.L., et al. The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight. Atherosclerosis 2010, 211:1-8.
69. Kersten S. Physiological regulation of lipoprotein lipase. Biochim. Biophys. Acta 1841, 2014:919-933.
70. Shan L., Yu X.C., Liu Z., et al. The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms. J. Biol. Chem. 2009, 284:1419-1424.
71. Kobayashi J., Miyashita K., Nakajima K., Mabuchi H. Hepatic lipase: a comprehensive view of its role on plasma lipid and lipoprotein metabolism. J. Atheroscler. Thromb. 2015, 22:1001-1011.
72. Sonnenburg W.K., Yu D., Lee E.C., et al. GPIHBP1 stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4. J. Lipid Res. 2009, 50:2421-2429.
73. Lillis A.P., Van Duyn L.B., Murphy-Ullrich J.E., Strickland D.K. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol. Rev. 2008, 88:887-918.
74. Stanford K.I., Bishop J.R., Foley E.M., et al. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J. Clin. Invest. 2009, 119:3236-3245.
75. Mendoza-Barbera E., Julve J., Nilsson S.K., et al. Structural and functional analysis of APOA5 mutations identified in patients with severe hypertriglyceridemia. J. Lipid Res. 2013, 54:649-661.
76. Leaf D.A. Chylomicronemia and the chylomicronemia syndrome. A practical guide to treatment. Am. J. Med. 2008, 121:10-12.
77. Gaudet D., Signorovitch J., Swallow E., et al. Medical resource use and cost associated with chylomicronemia. J. Med. Econ. 2013, 16:657-666.
78. Havel R.J. Pathogenesis, differentiation and management of hypertriglyceridemia. Adv. Intern. Med. 1969, 15:117-154.
79. Valdivielso P., Ramirez-Bueno A., Ewald N. Current knowledge of hypertriglyceridemic pancreatitis. Eur. J. Intern. Med. 2014, 25:689-694.
80. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308.
81. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309-316.
82. Zheng X.Y., Liu L. Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase. J. Lipid Res. 2007, 48:1673-1680.
83. Brunzell J.D., Hazzard W.R., Porte D., Bierman E.L. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J. Clin. Invest. 1973, 52:1578-1585.
84. Adiels M., Matikainen N., Westerbacka J., et al. Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity. Atherosclerosis 2012, 222:222-228.
85. Brunzell J.D., Bierman E.L. Chylomicronemia syndrome. Interaction of genetic and acquired hypertriglyceridemia. Med. Clin. North Am. 1982, 66:455-468.
86. Brunzell J.D. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. The Metabolic and Molecular Basis of Inherited Disease 1995, 1913-1932. McGraw-Hill, New York. 7 ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
87. Fredrickson D.S. An international classification of hyperlipidemias and hyperlipoproteinemias. Ann. Intern. Med. 1971, 75:471-472.
88. Hegele R.A. Plasma lipoproteins: genetic influences and clinical implications. Nat. Rev. Genet. 2009, 10:109-121.
89. Hayden M.R., Ma Y. Molecular genetics of human lipoprotein lipase deficiency. Mol. Cell. Biochem. 1992, 113:171-176.
90. Brunzell J.D., Miller N.E., Alaupovic P., et al. Familial chylomicronemia due to a circulating inhibitor of lipoprotein lipase activity. J. Lipid Res. 1983, 24:12-19.
91. Martin-Campos J.M., Julve J., Roig R., et al. Molecular analysis of chylomicronemia in a clinical laboratory setting: diagnosis of 13 cases of lipoprotein lipase deficiency. Clin. Chim. Acta 2014, 429:61-68.
92. Rabacchi C., Pisciotta L., Cefalu A.B., et al. Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemia. Atherosclerosis 2015, 241:79-86.
93. Rahalkar A.R., Giffen F., Har B., et al. Novel LPL mutations associated with lipoprotein lipase deficiency: two case reports and a literature review. Can. J. Physiol. Pharmacol. 2009, 87:151-160.
94. Wang J., Cao H., Ban M.R., et al. Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650). Arterioscler. Thromb. Vasc. Biol. 2007, 27:2450-2455.
95. Surendran R.P., Visser M.E., Heemelaar S., et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J. Intern. Med. 2012, 272:185-196.
96. Ariza M.J., Sanchez-Chaparro M.A., Baron F.J., et al. Additive effects of LPL, APOA5 and APOE variant combinations on triglyceride levels and hypertriglyceridemia: results of the ICARIA genetic sub-study. BMC Med. Genet. 2010, 11:66.
97. Semenkovich C.F., Chen S.H., Wims M., Luo C.C., Li W.H., Chan L. Lipoprotein lipase and hepatic lipase mRNA tissue specific expression, developmental regulation, and evolution. J. Lipid Res. 1989, 30:423-431.
98. Johansen C.T., Wang J., McIntyre A.D., et al. Excess of rare variants in non-genome-wide association study candidate genes in patients with hypertriglyceridemia. Circ. Cardiovasc. Genet. 2012, 5:66-72.
99. Kryukov G.V., Pennacchio L.A., Sunyaev S.R. Most rare missense alleles are deleterious in humans: implications for complex disease and association studies. Am. J. Hum. Genet. 2007, 80:727-739.
100. Desmarchelier C., Martin J.C., Planells R., et al. The postprandial chylomicron triacylglycerol response to dietary fat in healthy male adults is significantly explained by a combination of single nucleotide polymorphisms in genes involved in triacylglycerol metabolism. J. Clin. Endocrinol. Metab. 2014, 99:E484-E488.
101. Berglund L., Brunzell J.D., Goldberg A.C., et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2012, 97:2969-2989.
102. Martin-Campos J.M., Rico N., Bonet R., Mayoral C., Ordonez-Llanos J., Blanco-Vaca F. Apolipoprotein A5 S19W may play a role in dysbetalipoproteinemia in patients with the Apo E2/E2 genotype. Clin. Chem. 2006, 52:1974-1975.
103. Weintraub M.S., Eisenberg S., Breslow J.L. Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E. J. Clin. Invest. 1987, 80:1571-1577.
104. Rodrigues C.E., Bonfa E., Carvalho J.F. Review on anti-lipoprotein lipase antibodies. Clin. Chim. Acta 2010, 411:1603-1605.
105. Moret M., Pruneta-Deloche V., Sassolas A., Marcais C., Moulin P. Prevalence and function of anti-lipoprotein lipase auto-antibodies in type V hyperchylomicronemia. Atherosclerosis 2010, 208:324-327.
106. de Carvalho J.F., Viana V.S., Neto E.F., Santos R.D., Bonfa E. Anti-lipoprotein lipase antibodies in patients with hypertriglyceridemia without associated autoimmune disease. Isr. Med. Assoc. J. 2011, 13:350-353.
107. Pruneta V., Moulin P., Labrousse F., Bondon P.J., Ponsin G., Berthezene F. Characterization of a new case of autoimmune type I hyperlipidemia: long-term remission under immunosuppressive therapy. J. Clin. Endocrinol. Metab. 1997, 82:791-796.
108. Jones B., Jones E.L., Bonney S.A., et al. Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders. Nat. Genet. 2003, 34:29-31.
109. Wetterau J.R., Aggerbeck L.P., Bouma M.E., et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 1992, 258:999-1001.
110. Lee J., Hegele R.A. Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management. J. Inherit. Metab. Dis. 2014, 37:333-339.
111. Hooper A.J., Robertson K., Barrett P.H., Parhofer K.G., van Bockxmeer F.M., Burnett J.R. Postprandial lipoprotein metabolism in familial hypobetalipoproteinemia. J. Clin. Endocrinol. Metab. 2007, 92:1474-1478.
112. Musunuru K., Pirruccello J.P., Do R., et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N. Engl. J. Med. 2010, 363:2220-2227.
113. Martin-Campos J.M., Roig R., Mayoral C., et al. Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation. Clin. Chim. Acta 2012, 413:552-555.
114. Pisciotta L., Favari E., Magnolo L., et al. Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3. Circ. Cardiovasc. Genet. 2012, 5:42-50.
115. Minicocci I., Montali A., Robciuc M.R., et al. Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization. J. Clin. Endocrinol. Metab. 2012, 97:E1266-E1275.
116. Shimizugawa T., Ono M., Shimamura M., et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J. Biol. Chem. 2002, 277:33742-33748.
117. Romeo S., Yin W., Kozlitina J., et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J. Clin. Invest. 2009, 119:70-79.
118. Nakajima K., Kobayashi J., Mabuchi H., et al. Association of angiopoietin-like protein 3 with hepatic triglyceride lipase and lipoprotein lipase activities in human plasma. Ann. Clin. Biochem. 2010, 47:423-431.
119. Shimamura M., Matsuda M., Yasumo H., et al. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. Arterioscler. Thromb. Vasc. Biol. 2007, 27:366-372.
120. Moon H.D., Nakajima K., Kamiyama K., Takanashi K., Sakurabayashi I., Nagamine T. Higher frequency of abnormal serum angiopoietin-like protein 3 than abnormal cholesteryl ester transfer protein in Japanese hyperalphalipoproteinemic subjects. Clin. Chim. Acta 2008, 398:99-104.
121. Robciuc M.R., Maranghi M., Lahikainen A., et al. Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1706-1713.
122. Lindman A.S., Veierod M.B., Tverdal A., Pedersen J.I., Selmer R. Nonfasting triglycerides and risk of cardiovascular death in men and women from the Norwegian Counties Study. Eur. J. Epidemiol. 2010, 25:789-798.
123. Imke C., Rodriguez B.L., Grove J.S., et al. Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu Heart study. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1718-1722.
124. Varbo A., Benn M., Tybjaerg-Hansen A., Jorgensen A.B., Frikke-Schmidt R., Nordestgaard B.G. Remnant cholesterol as a causal risk factor for ischemic heart disease. J. Am. Coll. Cardiol. 2013, 61:427-436.
125. Schneeman B.O., Kotite L., Todd K.M., Havel R.J. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:2069-2073.
126. Cohn J.S., Johnson E.J., Millar J.S., et al. Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J. Lipid Res. 1993, 34:2033-2040.
127. Karpe F., Bell M., Bjorkegren J., Hamsten A. Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100. Arterioscler. Thromb. Vasc. Biol. 1995, 15:199-207.
128. Proctor S.D., Mamo J.C. Intimal retention of cholesterol derived from apolipoprotein B100- and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1595-1600.
129. Masuda D., Sugimoto T., Tsujii K., et al. Correlation of fasting serum apolipoprotein B-48 with coronary artery disease prevalence. Eur. J. Clin. Investig. 2012, 42:992-999.
130. Mori K., Ishida T., Yasuda T., et al. Fasting serum concentration of apolipoprotein B48 represents residual risks in patients with new-onset and chronic coronary artery disease. Clin. Chim. Acta 2013, 421:51-56.
131. Nakatani K., Sugimoto T., Masuda D., et al. Serum apolipoprotein B-48 levels are correlated with carotid intima-media thickness in subjects with normal serum triglyceride levels. Atherosclerosis 2011, 218:226-232.
132. Hogue J.C., Lamarche B., Tremblay A.J., Bergeron J., Gagne C., Couture P. Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes. J. Lipid Res. 2007, 48:1336-1342.
133. Mangat R., Su J.W., Lambert J.E., et al. Increased risk of cardiovascular disease in Type 1 diabetes: arterial exposure to remnant lipoproteins leads to enhanced deposition of cholesterol and binding to glycated extracellular matrix proteoglycans. Diabet. Med. 2011, 28:61-72.
134. Valdivielso P., Puerta S., Rioja J., et al. Postprandial apolipoprotein B48 is associated with asymptomatic peripheral arterial disease: a study in patients with type 2 diabetes and controls. Clin. Chim. Acta 2010, 411:433-437.
135. Lapice E., Cipriano P., Patti L., Romano G., Vaccaro O., Rivellese A.A. Fasting apolipoprotein B48 is associated with asymptomatic peripheral arterial disease in type 2 diabetic subjects: a case-control study. Atherosclerosis 2012, 223:504-506.
136. Mero N., Malmstrom R., Steiner G., Taskinen M.R., Syvanne M. Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. Atherosclerosis 2000, 150:167-177.
137. Phillips C., Murugasu G., Owens D., Collins P., Johnson A., Tomkin G.H. Improved metabolic control reduces the number of postprandial apolipoprotein B-48-containing particles in type 2 diabetes. Atherosclerosis 2000, 148:283-291.
138. Chung B.H., Tallis G., Yalamoori V., Anantharamaiah G.M., Segrest J.P. Liposome-like particles isolated from human atherosclerotic plaques are structurally and compositionally similar to surface remnants of triglyceride-rich lipoproteins. Arterioscler. Thromb. 1994, 14:622-635.
139. Pal S., Semorine K., Watts G.F., Mamo J. Identification of lipoproteins of intestinal origin in human atherosclerotic plaque. Clin. Chem. Lab. Med. 2003, 41:792-795.
140. Nakano T., Nakajima K., Niimi M., et al. Detection of apolipoproteins B-48 and B-100 carrying particles in lipoprotein fractions extracted from human aortic atherosclerotic plaques in sudden cardiac death cases. Clin. Chim. Acta 2008, 390:38-43.
141. Floren C.H., Chait A. Uptake of chylomicron remnants by the native LDL receptor in human monocyte-derived macrophages. Biochim. Biophys. Acta 1981, 665:608-611.
142. Elsegood C.L., Pal S., Roach P.D., Mamo J.C. Binding and uptake of chylomicron remnants by primary and THP-1 human monocyte-derived macrophages: determination of binding proteins. Clin. Sci. (Lond.) 2001, 101:111-119.
143. Elsegood C.L., Mamo J.C. An investigation by electron microscopy of chylomicron remnant uptake by human monocyte-derived macrophages. Atherosclerosis 2006, 188:251-259.
144. Botham K.M., Wheeler-Jones C.P. Postprandial lipoproteins and the molecular regulation of vascular homeostasis. Prog. Lipid Res. 2013, 52:446-464.
145. Domoto K., Taniguchi T., Takaishi H., et al. Chylomicron remnants induce monocyte chemoattractant protein-1 expression via p38 MAPK activation in vascular smooth muscle cells. Atherosclerosis 2003, 171:193-200.
146. Takahashi Y., Fujioka Y., Takahashi T., et al. Chylomicron remnants regulate early growth response factor-1 in vascular smooth muscle cells. Life Sci. 2005, 77:670-682.
147. Duez H., Lamarche B., Uffelman K.D., Valero R., Cohn J.S., Lewis G.F. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1357-1363.
148. Lally S., Tan C.Y., Owens D., Tomkin G.H. Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia 2006, 49:1008-1016.
149. Bozzetto L., Annuzzi G., Corte G.D., et al. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. Atherosclerosis 2017, 2011:142-148.
150. Levy E., Spahis S., Garofalo C., et al. Sar1b transgenic male mice are more susceptible to high-fat diet-induced obesity, insulin insensitivity and intestinal chylomicron overproduction. J. Nutr. Biochem. 2014, 25:540-548.
151. Farr S., Adeli K. Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states. Curr. Opin. Lipidol. 2012, 23:56-61.
152. Meier J.J., Gethmann A., Götze O., et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006, 49:452-458.
153. Vilsbøll T., Krarup T., Deacon C.F., Madsbad S., Holst J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001, 50:609-613.
154. Xiao C., Bandsma R.H., Dash S., Szeto L., Lewis G.F. Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1513-1519.
155. Schwartz E.A., Koska J., Mullin M.P., Syoufi I., Schwenke D.C., Reaven P.D. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 2010, 212:217-222.
156. Altomonte J., Cong L., Harbaran S., et al. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J. Clin. Invest. 2004, 114:1493-1503.
157. Farr S., Baker C., Naples M., et al. Central Nervous system regulation of intestinal lipoprotein metabolism by glucagon-like peptide-1 via a brain-gut axis. Arterioscler. Thromb. Vasc. Biol. 2015, 35:1092-1100.
158. Nakajima K., Nakano T., Tokita Y., et al. Postprendial lipoprotein metabolism: VLDL vs chylomicrons. Clin. Chim. Acta 2011, 412:1306-1318.
159. Nakajima K., Saito T., Tamura A., et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin. Chim. Acta 1993, 223:53-71.
160. Miyauchi K., Kayahara N., Ishigami M., et al. Development of a homogeneous assay to measure remnant lipoprotein cholesterol. Clin. Chem. 2007, 53:2128-2135.
161. Nakamura T., Obata J.E., Hirano M., et al. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals. Atherosclerosis 2011, 218:163-167.
162. Phillips M.L., Pullinger C., Kroes I., et al. A single copy of apolipoprotein B-48 is present on the human chylomicron remnant. J. Lipid Res. 1997, 38:1170-1177.
163. Brunzell J.D. Familial Lipoprotein Lipase 1999, University of Washinton, Seattle (WA). R.A. Pagon, M.P. Adam, H.H. Ardinger (Eds.).
164. Shearer G.C., Savinova O.V., Harris W.S. Fish-oil-how does it reduce plasma triglicerides?. Biochim. Biophys. Acta 2012, 182:843-851.
165. Ferreira V., Twisk J., Kwikkers K., et al. Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy. Hum. Gene Ther. 2014, 25:180-188.
166. Scott L.J. Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency. Drugs 2015, 75:175-182.
167. Gaudet D., Brisson D., Tremblay K., et al. Targeting APOC3 in the familial chylomicronemic syndrome. N. Engl. J. Med. 2014, 371:2200-2206.
168. Gaudet D., Alexander V.J., Baker B.F., et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N. Engl. J. Med. 2015, 373:438-447.